Fredrik Gruenenfelder

Statistics

Publications

Citations

517

H-Index

Active since

2006

Affiliations

Boehringer Ingelheim (United States)(Current)

Boehringer Ingelheim (Germany)

Duke Medical Center

Max Planck Institute of Experimental Medicine

University of Glasgow

Fredrik Gruenenfelder is an author at Boehringer Ingelheim (United States) specializing in medicine, idarucizumab reversal, and clinical pharmacology.

Publications per year

2006–2025

Publications

Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial

Stephan Glund, Joachim Stangier, Michael Schmohl et al. · The Lancet · 2015 · 318 citations

Medicine, Pharmacology, Pharmacotherapy +10

Demyelination and axonal preservation in a transgenic mouse model of Pelizaeus‐Merzbacher disease

Julia M. Edgar, Mailis C. McCulloch, Paul Montague et al. · EMBO Molecular Medicine · 2010 · 73 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program

John Fanikos, Debra Murwin, Fredrik Gruenenfelder et al. · Thrombosis and Haemostasis · 2019 · 48 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Neural stem cells restore myelin in a demyelinating model of Pelizaeus-Merzbacher disease

Fredrik Gruenenfelder, Ian R. Griffiths, James Garbern et al. · Brain · 2020 · 25 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Intraaxial Spinal Cord Hemorrhage Secondary to Atlantoaxial Subluxation in a Dog

Marc Kent, Joseph S. Eagleson, Dharshan Neravanda et al. · Journal of the American Animal Hospital Association · 2010 · 21 citations

Medicine, Neurosurgery, Veterinary Surgery +17

1–5 of 8